

Rx Guide delivers personalized and actionable insights to drive solutions

Helps you understand what is driving key spend and predicts savings


Rx Guide is an interactive self-service reporting and analytics tool that makes pharmacy data easier to access and understand. It can be used by clients, consultants, and account managers alike. It uncovers deep pharmacy insights so you can see what's driving key spend metrics.

Rx Guide gathers data from pharmacy claims, clinical programs, providers, and utilization management to provide understanding on trends, cost drivers, industry benchmarks, and engagement. It also models different product solutions with plan-specific saving opportunities and effects based on your specific membership. With over 80 dashboards, you can have a comprehensive view of your business in a format best suited to your needs.

Rx Guide offers a customizable experience so you can quickly dive into key focus areas.

Create client-specific dashboards

All categories are variable at any segment of the business with industry-specific benchmarks so you can see the full picture.



- Total plan cost
- Plan cost per member per month (PMPM)
- Program savings
- Average number of members per month
- Non-specialty PMPM
- Specialty PMPM
- Adjusted Rx's PMPM
- Generic fill rate

Filter high-cost claimants to understand drivers behind key spend metrics

- Customize thresholds for high-cost claimants and filter by claim type.
- See how the average wholesale price affects plan cost.
- View high-cost drugs by indication and PMPM cost/trends.
- Track newly added drugs.
- See how you rank against peers.

HCC: Top Indications (HCC ≥ \$10.0k - Filtered)

RANK	INDICATION	PLAN COST	PPPM	RXS	RX TREND	PTS
1 ↑	HEPATITIS C	\$150,268	\$25,044.60	6	-%	2
2 —	PULMONARY HYPERTENSION	\$499,495	\$14,691.02	34	1033.33 %	1
3 ↓	ENDOCRINE DISORDERS	\$175,453	\$10,965.83	16	-5.88 %	3
4 ↑	INFLAMMATORY CONDITIONS	\$1,054,995	\$7,581.10	14	-	1
5 —	MULTIPLE SCLEROSIS	\$30,319	\$7,581.10	4	-	1
6 ↓	BLOOD CELL DEFICIENCY	\$97,029	\$7,442.42	11	-	1
7 —	CYSTIC FIBROSIS	\$14,721	\$4,973.67	4	-	1
8 ↑	GROWTH DEFICIENCY	\$62,288	\$4,711.40	4	-	1

HCC: Top Drugs (HCC ≥ \$10.0k - Filtered)

RANK	DRUG NAME	PLAN COST	PPPM	SPCLTY	RXS	RX TREND
1 ↑	EPCLUSA	\$150,268	\$25,044.60	Y	6	-%
2 ↓	FENSOLVI	\$96,613	\$24,153.27	Y	4	300.00 %
3 ↑	UPTRAVI	\$227,653	\$20,695.69	Y	11	-%
4 —	JYNARQUE	\$69,804	\$17,451.10	Y	4	-66.67 %
5 —	SKYRIZI	\$17,432	\$17,432.24	Y	1	-75.00 %
5 ↑	SKYRIZI PEN	\$174,322	\$17,432.24	Y	10	-%
7 ↑	ILARIS	\$187,326	\$17,029.61	Y	11	-%
8 ↑	VERZENIO	\$55,380	\$13,844.88	Y	4	-%

Model plan changes

Learn how CarelonRx products boost your bottom line through our predictive analytics. Compare current and future states, model value opportunities, and track the effectiveness of clinical management programs over time.

- View the savings achieved through a change in formulary.
- Model the member disruption and savings achieved through a change in network.

MAIN 📄

VIEW OPTIMAL SAVINGS Current settings are for optimized savings.

1. Formulary

Current: Essential

Future: Essential

2. Retail Network

Current: Base

Future: Rx Choice

3. 90-Day Network

Current: Optional Home Delivery

Future: Retail 90

4. Solutions

Specialty Cost Optimization

Current Future

Clinical Outreach Programs

Care Optimization Current Future

Rx Care Nexus Current Future

Specialty Copay Assistance

Specialty Drug Accumulator Rules Current Future

Cost Relief Current Future

Specialty Condition Management

Specialty Condition Management Enhanced Current Future

CLEAR **GO ->**



Find out more

To schedule a live demo, please email RxGuide@carelon.com or contact your sales or account management representative.

